On 18 September the published guidance on the listing of cannabis-based businesses onto public stock exchanges in the UK. We consider the...
This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Add a bookmark to get started
Global Site
Back
Cortex - Life Sciences Insights
Research undertaken by DLA Piper's Life Sciences sector in conjunction with The Lawyer seeks to understand the current developments in...
As the medical and healthcare sectors remain firmly focused on tackling the many and ongoing challenges of COVID-19, the Australian...
We previously reported in our article “Developments in Australian CBD market” that the Pharmaceutical Benefits Advisory Committee (PBAC)...
DLA Piper is a global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA Piper's structure, please refer to the Legal Notices page of this website. All rights reserved. Attorney advertising.
© 2023 DLA Piper
Email Disclaimer
Unsolicited e-mails and information sent to DLA Piper or the independent DLA Piper Relationship firms will not be considered confidential, may be disclosed to others, may not receive a response, and do not create a lawyer-client relationship with DLA Piper or any of the DLA Piper Relationship firms. Please do not include any confidential information in this message. Also, please note that our lawyers do not seek to practice law in any jurisdiction in which they are not properly permitted to do so.
